SRPT - Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4 $200M For Fiscal Year | Benzinga
Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) reported preliminary FY23 net product revenue of $1.145 billion.
The Cambridge, Massachusetts-based company said preliminary Elevidys net product revenue is expected to be $131.3 million for Q4 and $200.4 million for FY23, significantly exceeding consensus.
Fourth quarter and full-year 2023 net product revenue for Sarepta's RNA-based PMOs are expected to be approximately $234.3 million and $945.0 million, respectively.
As of Dec. 31, 2023, Sarepta had preliminary cash, cash equivalents, restricted cash, and investments of approximately $1.7 billion.
Also Read: Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces ...